Anzeige
Meldung des Tages: Parlaments-Wahl am 08.03.2026: Ist das der Gratis-Katalysator für diese Aktie?

Sanofi Aktie

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF Branche:  Pharmazeutika Land:  Frankreich
95,02 $
-0,02 $
-0,02%
80,392 € 23.02.26
Depot/Watchlist
Marktkapitalisierung *
102,65 Mrd. €
Streubesitz
43,33%
KGV
10,68
Dividende
3,92 EUR
Dividendenrendite
4,76%
Nachhaltigkeits-Score
68 %
Index-Zuordnung
Euro Stoxx 50
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,38: UJ4AML
Werbung

Ad-hocs

17.09.25 - GlobeNewswire
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary ...
11.09.25 - GlobeNewswire
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-​related macular degeneration Designation earned for a one-time intravitreal gene therapy with the ...
10.09.25 - GlobeNewswire
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Tzield approved in China as first disease-​modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
29.08.25 - GlobeNewswire
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-​immune modulation to help address root causes of ...
14.08.25 - GlobeNewswire
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related ...
06.08.25 - GlobeNewswire
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
Sanofi completes the acquisition of Vigil Neuroscience, Inc.
31.07.25 - GlobeNewswire
Press release: Online availability of Sanofi’s half-year financial report for 2025
Online availability of Sanofi’s half-year financial report for 2025
31.07.25 - GlobeNewswire
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Q2: double-​digit sales and solid business EPS growth. 2025 sales guidance is now high single-​digit growth, at upper end of range
30.07.25 - GlobeNewswire
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
25.07.25 - GlobeNewswire
Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-​eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that ...
22.07.25 - GlobeNewswire
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a ...
18.07.25 - GlobeNewswire
Press Release: Sanofi completes acquisition of Blueprint Medicines
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025 . Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), ...
17.07.25 - GlobeNewswire
Press Release: Sanofi announces extension of Blueprint tender offer
Sanofi announces extension of Blueprint tender offer Paris, July 17, 2025 . Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended ...
16.07.25 - GlobeNewswire
Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-​related macular degeneration
30.06.25 - GlobeNewswire
Press release: Availability of the Q2 2025 Aide mémoire
30.06.25 - GlobeNewswire
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in ...
25.06.25 - GlobeNewswire
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Riliprubart earns orphan drug designation in the US for antibody-​mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential ...
23.06.25 - GlobeNewswire
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-​eligible newly diagnosed multiple myeloma
20.06.25 - GlobeNewswire
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
17.06.25 - GlobeNewswire
Press release: Sanofi successfully prices €1.5 billion bond issue
Sanofi successfully prices €1.5 billion bond issue

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »